Partnering Opportunities  
     
  Plexxikon's unique discovery platform allows for the creation of novel, competitively differentiated drugs that have improved pharmacologic properties over many of today's available therapies.

The company has demonstrated the ability to move multiple programs from discovery to IND in just two years, significantly improving typical pharmaceutical development timelines at reduced costs.

Plexxikon is seeking collaborations with companies for a number of programs for which the company expects to file INDs during the next six to 12 months.

Current unpartnered programs include opportunities in:
CNS: Pain Program Fact Sheet
Inflammation: Rheumatoid Arthritis Program Fact Sheet
Oncology: Metastatic Bone Lesions Program Fact Sheet

[Please provide all pdf fact sheets]
 
     
       
Metabolic Disease Oncology Inflammation CNS Cardiovascular Partners
 
 
     
  Partnering Opportunities  
     
  Plexxikon’s unique discovery platform allows for the creation of novel, competitively differentiated drugs that have improved pharmacologic properties over many of today's available therapies.

The company has demonstrated the ability to move multiple programs from discovery to IND in just two years, significantly improving typical pharmaceutical development timelines at reduced costs.

Plexxikon is seeking collaborations with companies for a number of programs for which the company expects to file INDs during the next six to 12 months.

Current unpartnered programs include opportunities in:
CNS: Pain Program Fact Sheet
CNS: Multiple Sclerosis Program Fact Sheet
Inflammation: Rheumatoid Arthritis Program Fact Sheet
Oncology: Osteolytic Metastatic Disease Program Fact Sheet
   
  Product Pipeline
 
     
 
Metabolic Disease | Oncology | Inflammation | CNS | Cardiovascular | Partners
Home | About Plexxikon | Investors | News | Clinical Trials | Careers | Contact Us | Site Map
© 2007 Plexxikon Inc. | Site design by Heiney & Craig